Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT06951464 2025-07-23

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Phase 2 Recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06752408 2024-12-30

ANOTHER

316 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06604689 2024-11-12

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

Recruiting

800 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04685070 2024-08-14

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

56 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06463171 2024-06-17

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

91 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06185400 2023-12-29

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

108 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04401059 2023-12-27

SELECT-2

Phase 4 Unknown

744 enrolled

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05662813 2022-12-23

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

55 enrolled

Carcinoma, Non-Small-Cell Lung, Digestive System Diseases, Liver Diseases

NCT04755738 2021-09-05

MWA

234 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04978753 2021-07-27

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

54 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04952168 2021-07-07

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04944069 2021-06-29

ATTRACT

Phase NA Unknown

69 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04905550 2021-06-02

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

50 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04636593 2021-01-12

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

43 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiation Pneumonitis

NCT04592666 2020-10-19

APPEAL

226 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04553887 2020-10-14

AUTUMN

53 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04500704 2020-08-05

ACROSS1

Phase 3 Unknown

166 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04500717 2020-08-05

ACROSS2

Phase 3 Unknown

460 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04455594 2020-07-02

ANSWER

168 enrolled